NanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergency
NanoViricides (NYSE-A:NNVC) is preparing for Phase II clinical testing in Africa, following the World Health Organization's recent extension of the Public Health Emergency of International Concern (PHEIC) for the Mpox virus outbreak. The extension, announced on July 10, comes amid rising cases of the Clade I strain of the Mpox virus (MPXV) in Africa, and sporadic travel-related cases outside the region, including the US, that pose a risk of sustained transmission.
NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks
NanoViricides (NYSE-A:NNVC) is preparing to launch a Phase 2 clinical trial of its lead antiviral candidate NV-387 for the treatment of Mpox Clade I in the Democratic Republic of Congo (DRC), following ethics approval from the country's health ministry in May, according to a research note by Zacks Small Cap Research. The trial will test the efficacy and safety of NV-387, a broad-spectrum antiviral developed using NanoViricides' proprietary nanomedicine platform, in up to 80 hospitalized patients.
NanoViricides nears completion of clinical trial design for MPox treatment
NanoViricides (NYSE-A:NNVC) said on Monday it is close to finalizing the design of a Phase II adaptive clinical trial for its lead candidate NV-387 to treat MPox virus Clade 1a and 1b infections. The trial aims to assess safety, tolerability, and antiviral effectiveness in approximately 80 patients, with the initial Phase IIa portion to be conducted at a single site in the Democratic Republic of Congo (DRC).
NanoViricides advances antiviral candidate NV-387 into Phase 2 trials for Mpox
NanoViricides (NYSE-A:NNVC) announced it is moving forward with Phase 2 clinical development of its experimental antiviral therapy, NV-387, for the treatment of Mpox. The company has selected Mpox as the first indication among several viral targets studied in preclinical models, including RSV, influenza, and COVID-19.
NanoViricides touts antiviral NV-387 as tool against new COVID variant
NanoViricides (NYSE-A:NNVC) said its experimental antiviral drug NV-387 could play a role in combating emerging threats from COVID-19 and bird flu, as new virus variants raise global health concerns. The company pointed to the rise of the COVID variant NB.1.8.1, or "Nimbus," which is spreading in the US and globally.
NanoViricides commissions animal study of broad-spectrum antiviral for measles
NanoViricides (NYSE-A:NNVC) said it is advancing its measles drug development program with a new animal trial to evaluate its antiviral candidate NV-387. The company has commissioned a study using specially modified mice that express the human SLAM/CD150 protein, a key receptor the measles virus uses to infect cells.
NanoViricides president backs FDA's targeted COVID booster policy shift
NanoViricides (NYSE-A:NNVC) president Dr Anil Diwan has welcomed a new US Food and Drug Administration policy that limits broad COVID-19 vaccine booster recommendations, calling it a “rational and scientific” shift that could help restore public trust in health institutions. The updated FDA guidance recommends COVID booster shots only for adults aged 65 and older, and for individuals aged six months and above with underlying conditions that put them at risk of severe disease.
NanoViricides advances NV-387 antiviral program, eyes Phase II trials for Mpox
NanoViricides (NYSE-A:NNVC) is preparing a Phase II clinical trial application for its lead antiviral candidate NV-387 to treat Mpox infections in Central Africa, marking a major step in the company's broader strategy to address a growing range of viral public health threats with no currently approved treatments. The Connecticut-based biotech firm recently received clearance from the Democratic Republic of Congo's National Ethics Committee to proceed with the submission following a review of Phase I safety data and promising results from preclinical Mpox studies in lethal animal models.
NanoViricides progresses antiviral portfolio as measles and MPox threats rise
NanoViricides Inc (NYSE American: NNVC) said on Wednesday it is moving forward with trials of its antiviral drug NV-387 to combat a growing number of viral threats, including measles and MPox, amid rising concern over vaccine failure and the lack of effective treatments. The Shelton, Connecticut-based company said it has initiated animal efficacy studies to evaluate NV-387 as a treatment for measles, noting there are currently no approved antiviral drugs for the disease.
NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC
NanoViricides (NYSE-A:NNVC) said on Thursday it has received ethics committee approval in the Democratic Republic of Congo to move forward with a planned Phase II clinical trial of its antiviral drug NV-387 for treating Mpox, a step toward regulatory submission in a region where the disease continues to spread. The approval, granted by the National Ethics Committee for Health (CNES) under the DRC's Ministry of Public Health, clears the company to submit a full clinical trial application (CTA) for NV-387, NanoViricides said.
NanoViricides advances measles drug development amid rising US cases
NanoViricides (NYSE-A:NNVC) said it is moving forward with the development of a drug to treat measles, as US health officials report a continuing rise in infections amid declining vaccination rates. The Shelton, Connecticut-based biotechnology firm said it has completed propagation of the measles virus in its biosafety level-2 virology lab and is preparing to conduct an animal model study to test its clinical-stage antiviral candidate NV-387.
NanoViricides evaluating antiviral drug NV-387 for measles treatment
NanoViricides (NYSE-A:NNVC) has begun evaluating its clinical-stage antiviral NV-387 for the treatment of measles, a disease with no currently approved drug treatment. “A drug for measles is at present a completely missing link in the response to measles virus outbreak,” said Anil Diwan, executive chairman of NanoViricides.
